Loading patent…
AssigneeIDEC Pharmaceuticals Corporation
InventorsPeter Brams, Phillip R. Morrow
Estimating the term…
A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein ≦2×10-−9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
A human monoclonal antibody which specifically binds the RSV fusion protein and which possesses an affinity for the RSV F-protein of ≦2×10−9 molar.
A human monoclonal antibody which specifically binds to the RSV fusion protein which is selected from the group consisting of RF-1 RF-2 and recombinant human monoclonal antibodies which contain the variable heavy and light domains of either RF-1 or RF-2.
Eukaryotic cells which have been transfected with DNA sequences which encode for the heavy and light variable domains of either RF-1 or RF-2.
An Epstein-Barr immortalized B cell line which secretes a human monoclonal antibody which possesses an affinity for the RSV fusion protein of ≦2×10−9 molar.
A method for producing human antibodies specific to the RSV fusion (F) protein which comprises:
A DNA sequence which encodes for the variable heavy and/or variable light domain of RF-1 or RF-2.
A method for preventing or treating RSV infection in susceptible or RSV infected persons which comprises administering a prophylactically or therapeutically effective amount of one or more human monoclonal antibodies which possess an affinity to the RSV F-protein of ≦2×10−9 molar and which also neutralize RSV in vitro.
A pharmaceutical composition suitable for preventing or treating RSV infection in susceptible or RSV infected persons which comprises a prophylactically or therapeutically effective amount of human monoclonal antibodies which neutralize RSV in vitro and which possess an affinity for the RSV F-protein of ≦2×10−9 molar and a pharmaceutically acceptable carrier.
A method of detecting the presence of RSV in an analyte which comprises incubating, said analyte with a human monoclonal antibody which possesses an affinity for the RSV F-protein of ≦2×10−9 molar under conditions which provide for the formation of RSV F-protein antibody immune complexes;
A test kit for assaying the presence of RSV in an analyte which comprises:
Dependencies are inferred from the claim text.